USPTO serial 79333600
MEGABULB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 7, 2023
- Examiner
- BLANE, SUZANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEGABULB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Nucleic acid comprising natural and unnatural nucleotides for scientific and research purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for scientific and research purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for scientific and research purposes; all the aforesaid goods for use in nanotechnology applications in the nature of data storage, data retrieval and computing for scientific and research purposes; nucleic acids or nucleic acid analogues for labelling, imaging and sensing applications for scientific and research purposes; nucleic acids or nucleic acid analogues as smart materials in the nature of smart therapeutic reagents and assays for scientific and research purposes; two-dimensional and three-dimensional nucleic acids or nucleic acid analogues for creating nanostructures and scaffolds for scientific and research purposes; chemical preparations, enzymes and DNA for the preparation of nucleic acid for scientific research; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for use in scientific research in the field of agri-biotechnology and nanotechnology; nucleic acids comprising natural and unnatural nucleotides for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; nucleic acid analogues with organic and inorganic chemicals for laboratory use in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for laboratory use in smart materials in the nature of smart therapeutic reagents and assays; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for laboratory use in creating nanostructures and scaffolds | ACTIVE | — |
| 005 | Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials in the nature of smart therapeutic reagents and assays; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds | ACTIVE | — |
| 009 | Electronic components, namely, nucleic acid analogues in the nature of electric wires, semi-conductors, transistors, rectifiers, diodes, light emitting diodes and energy storage systems in the nature of batteries and electrochemical devices configured for energy storage, namely electrolysers, all comprising nucleic acids or nucleic acid analogues; parts and fittings for all the aforesaid technology and parts and fitting for all the aforesaid goods, namely, electrical cables, display screens, transmitters | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LightBio Limited
- Other trademarks owned by LightBio Limited
- Other trademarks owned by LightBio Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Similar marks named MEGABULB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 4, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 12, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 11, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 7, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 7, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 7, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 21, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 20, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 20, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 30, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 30, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 30, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 10, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 8, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 8, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 8, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 17, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 25, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 25, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 28, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 26, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 22, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 17, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |